1. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma;Eggermont;NEJM Evidence,2022
2. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238;Larkin;Clinical cancer research,2023
3. Adjuvant immune checkpoint blockade revisited;van Doorn;The Lancet Oncology,2023
4. The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022;Ascierto;BioMed Central,2023
5. Common Toxicities associated with Immune Checkpoint Inhibitors and Targeted Therapy in the Treatment of Melanoma: A Systematic Scoping Review;Egeler;Critical Reviews in Oncology/Hematology,2023